Chondrosarcoma

Chondrosarcoma of the jaws is a malignant neoplasm of mesenchymal origin characterized by the production of cartilaginous (chondroid) matrix by neoplastic cells.[1][2] It is a locally aggressive tumor with a high propensity for local recurrence and a generally indolent but persistent clinical course.[3][4] The jaws are an uncommon site, accounting for a small fraction of all chondrosarcomas; head and neck chondrosarcomas collectively represent 1–12% of all chondrosarcomas.[1][5] The maxilla, particularly the anterior alveolar process and premaxilla, is the predominant jaw site, reflecting the presence of residual cartilaginous rests from embryologic development at the midline and parasagittal regions.[3][6] The signature radiographic pattern is an expansile mass with chondroid matrix calcification and bone destruction. Wide surgical excision is the primary treatment.[4][7]

• The 2020 WHO Classification of Tumours of Soft Tissue and Bone classifies chondrogenic malignancies into several subtypes: conventional (central) chondrosarcoma (grades I–III), dedifferentiated, mesenchymal, clear cell, and periosteal chondrosarcoma.[8][9]
• The term atypical cartilaginous tumor (ACT) is reserved for low-grade intracompartmental appendicular tumors; for axial tumors (including the jaws), the designation chondrosarcoma, grade I is retained.[8][9]
• Older literature may use the term "myxoid chondrosarcoma" for tumors with prominent myxoid matrix change; this is now considered a morphologic descriptor within conventional chondrosarcoma rather than a distinct subtype in the WHO classification.[10]
• Mesenchymal chondrosarcoma is a separate, high-grade entity with distinct biphasic histology and should not be confused with conventional chondrosarcoma.[8][11]

• Chondrosarcoma of the jaws is rare. In a pooled review of 224 jaw chondrosarcomas, there was a slight male predominance, and most patients were in the second through fifth decades of life.[4]
• The maxilla is the most commonly affected jaw bone, particularly the anterior alveolar ridge and premaxillary region. The mandible is less frequently involved; when affected, the symphysis, body, and condylar region are reported sites.[3][4][6][12][13]
• In the largest single-institution jaw series (56 cases), 44.6% involved the alveolar maxilla/maxillary sinus and 10.7% involved the mandible.[3]
• Mesenchymal chondrosarcoma of the jaws affects a younger population (median age ~28 years) and also favors the maxilla.[11]

Symptoms and Signs

• The most common presentation is a painless, slowly enlarging mass or swelling. The median interval from first symptom to treatment is approximately one year.[3][4][12]
• Pain, when present, is typically a late finding. Numbness or paresthesia of the inferior alveolar nerve distribution is occasionally reported in mandibular lesions.[13][14]
• Loosening and displacement of teeth in the affected region is a characteristic finding. Dental mobility may be the initial complaint, and the lesion may mimic periodontal or periapical disease.[15][16][17]
• Maxillary tumors may cause nasal obstruction, epistaxis, or palatal expansion depending on extent.[3][18]

Tempo and Red Flags

• Low-grade tumors grow slowly over months to years; rapid enlargement, pain, or paresthesia should raise concern for higher-grade disease or dedifferentiation.[11][19]
• Mesenchymal chondrosarcoma behaves more aggressively, with higher rates of recurrence and distant metastasis.[11]

Location and Distribution

• In the maxilla, chondrosarcoma most commonly arises in the anterior alveolar process and premaxillary region, often extending into the maxillary sinus or nasal cavity. In the mandible, the symphysis, body, and condylar/TMJ region are reported sites.[3][4][12][13]
• The predilection for the anterior maxilla is attributed to residual cartilaginous rests at sites of embryologic fusion.[6]

Periphery and Shape

• Jaw chondrosarcomas typically present as expansile, lobulated masses. The periphery is variable:[3][18]
  • Low-grade tumors may show relatively well-defined margins with sharp transitional zones and sclerotic borders, mimicking benign processes.[18][19]
  • Higher-grade tumors demonstrate ill-defined, irregular, and infiltrative margins with frank bone destruction.[2][3]
• Periosteal reaction is characteristically absent or minimal in craniofacial chondrosarcomas, a useful distinguishing feature from osteosarcoma.[18]

Internal Architecture

• The hallmark internal finding is chondroid matrix calcification, which appears as scattered, stippled, or flocculent radiopacities within the lesion. When well developed, these calcifications assume the classic "ring-and-arc" pattern representing enchondral ossification at the periphery of cartilage lobules.[2][20][21]
• Matrix calcification is present in the majority of cases but varies in conspicuity; approximately 79% of jaw/facial chondrosarcomas with available imaging demonstrate calcified matrix within an expanding soft tissue mass.[3]
• A minority of lesions are purely radiolucent (lytic) without visible calcification, particularly when small or when the chondroid matrix is predominantly unmineralized.[3][18]
• Mixed radiolucent-radiopaque patterns are common, with irregular radiopacity interspersed within a predominantly radiolucent background.[13]

Effects on Teeth and Adjacent Structures

• Displacement and loosening of teeth are frequently observed. Widening of the periodontal ligament space around teeth within the lesion may occur and can mimic periodontal disease or osteosarcoma.[15][16][17][22]
• Root resorption of adjacent teeth is reported in some cases but is not a consistent feature.[13]
• Extension into the maxillary sinus, nasal cavity, or orbit may be seen with maxillary tumors. Mandibular lesions may involve the inferior alveolar canal.[3][18]

Growth Pattern and Cortical Involvement

• Chondrosarcomas grow in a lobular pattern, expanding and eroding cortical bone. Cortical thinning, expansion, and perforation with soft tissue extension are common, particularly in larger or higher-grade tumors.[2][3][18]
• Endosteal scalloping—erosion of the inner cortical surface—is a feature that, when deep (greater than two-thirds of cortical thickness), favors malignancy over a benign cartilaginous lesion.[2]
• Despite cortical destruction, the slow growth rate often results in a relatively well-demarcated soft tissue component.[18]

Extent

• Tumors are often large at detection due to their slow growth and initially asymptomatic nature. CBCT is more accurate than panoramic radiography for assessing cortical thinning, expansion, destruction, and the three-dimensional extent of intraosseous jaw lesions.[18][23][24]

Variants

• TMJ/condylar chondrosarcoma: Arises from or centered on the mandibular condyle, with outward growth from the medullary cavity and characteristic infiltration into the tendon of the lateral pterygoid muscle at the pterygoid fovea. Absent or stippled calcification and periosteal reaction may be seen. These lesions are frequently misdiagnosed as synovial chondromatosis or chondroma preoperatively.[19][25][26]
• Mesenchymal chondrosarcoma: May present with more aggressive radiographic features, including ill-defined margins and rapid bone destruction, reflecting its higher-grade biology.[11]

Medical CT

• CT is the optimal modality for detecting and characterizing chondroid matrix mineralization, particularly when calcification is subtle or the lesion is in an anatomically complex area such as the maxilla or skull base. CT demonstrates the expansile mass with cortical destruction and internal calcification that suggests bony or cartilaginous origin.[2][27][28]
• Low-grade tumors may show cortical thickening and matrix calcifications; high-grade tumors demonstrate cortical destruction, endosteal scalloping, and periosteal reactions.[28]

MRI

• MRI is the preferred modality for assessing soft tissue extent, marrow involvement, and staging.[2][29]
• Chondrosarcomas characteristically show low to intermediate signal on T1-weighted images and very high signal intensity on T2-weighted images, reflecting the high water content of hyaline cartilage.[2][30]
• Signal heterogeneity on T2-weighted images results from matrix mineralization and fibrocartilaginous elements.[30]
• After gadolinium administration, low-grade tumors demonstrate a characteristic septal or "ring-and-arc" enhancement pattern corresponding to fibrovascular septa surrounding non-enhancing cartilage lobules. High-grade tumors show more diffuse, heterogeneous enhancement with central non-enhancing areas representing necrosis.[31][32][33]
• TMJ chondrosarcomas show markedly hyperintense T2 signal areas that do not enhance, with mixed peripheral and internal enhancement.[25]

PET/CT

• FDG uptake is variable; higher SUV values (>4) have been associated with higher-grade tumors and may predict relapse, but low-grade tumors may show FDG uptake lower than that of the liver.[25][28]

Jaw chondrosarcoma enters the differential of any expansile jaw mass with internal calcification or mixed radiolucent-radiopaque architecture. The key diagnostic challenge is distinguishing low-grade chondrosarcoma from benign chondrogenic lesions and separating it from chondroblastic osteosarcoma.

The highest-risk diagnostic pitfall is misidentifying a low-grade chondrosarcoma as a benign chondroma or synovial chondromatosis, leading to inadequate initial surgery. Incisional biopsy is essential for any chondrogenic jaw lesion with aggressive features; IDH1/2 mutation analysis can help confirm chondrosarcoma over chondroblastic osteosarcoma when histologic distinction is uncertain.[35]

Conventional Chondrosarcoma

• Defined by the production of hyaline cartilaginous matrix by malignant cells without neoplastic osteoid or bone formation.[2][37]
• Tumors grow with a lobulated architecture; cartilage lobules are separated by fibrovascular septa and may permeate pre-existing host bone trabeculae, a key criterion for malignancy.[36][38]
• Grading (I–III) is based on cellularity, nuclear size and atypia, presence of binucleation/multinucleation, mitotic activity, and matrix composition:[37][39]
  • Grade I: Low cellularity, abundant hyaline matrix, mild nuclear atypia, no mitoses. Rarely metastasizes.[37]
  • Grade II: Increased cellularity, moderate nuclear atypia, hyperchromasia, myxoid matrix change.[37][38]
  • Grade III: High cellularity, severe pleomorphism, mitoses, sparse matrix, necrosis.[37]
• Most jaw chondrosarcomas are grade I or II; grade III is uncommon in this location.[3][4]
• Interobserver variability in grading is well documented, particularly at the grade I/II boundary.[36]

Radiologic-Pathologic Correlation

• The lobulated growth pattern corresponds to the lobulated contour on imaging. Chondroid matrix mineralization on radiographs reflects enchondral ossification at the periphery of cartilage lobules. Myxoid matrix change correlates with areas of lower attenuation on CT and higher T2 signal on MRI.[2][40]

Mesenchymal Chondrosarcoma

• Characterized by a biphasic pattern: islands of well-differentiated hyaline cartilage admixed with sheets of small, round, undifferentiated mesenchymal cells.[8][11]
• Immunohistochemistry shows positivity for CD99 (64.7%) and S100 (58.8%).[11]

Molecular Findings

• Approximately 50–70% of central conventional chondrosarcomas harbor IDH1 or IDH2 mutations. However, chondrosarcomas of the facial skeleton (intramembranous bone) notably lack IDH mutations, in contrast to skull base tumors (endochondral bone) where IDH mutation rates reach ~86%. This site-specific molecular difference may reflect distinct pathogenetic mechanisms related to the type of ossification.[12][41][42]
• IDH1/2 mutation analysis is a useful adjunct to distinguish chondrosarcoma from chondroblastic osteosarcoma, which uniformly lacks these mutations.[35]

Workup and Referral

• Any jaw mass with imaging features suggestive of a chondrogenic malignancy warrants incisional or core needle biopsy before definitive surgery. Biopsy should be performed at or coordinated with the center that will provide definitive management.[7]
• Multidisciplinary evaluation including oral and maxillofacial surgery, head and neck surgical oncology, musculoskeletal pathology, and radiation oncology is recommended.[7]

Definitive Treatment

• Wide surgical excision with histologically negative margins is the treatment of choice for jaw chondrosarcoma. In the jaws, this typically requires segmental resection (partial maxillectomy or segmental mandibulectomy).[3][4][7][43]
• There are no standard effective chemotherapy regimens for conventional chondrosarcoma (grades I–III); ivosidenib is an option for tumors with susceptible IDH1 mutations.[7]
• Radiation therapy is considered for borderline resectable or unresectable tumors, or as adjuvant treatment for positive surgical margins. Specialized techniques (proton beam, carbon ion, IMRT) are preferred to achieve doses ≥70 Gy while sparing adjacent structures.[7]
• Radical surgery combined with adjuvant radiotherapy has been associated with improved prognosis compared with surgery alone in some analyses.[4]

Recurrence and Prognosis

• Local recurrence rates are substantial, reported at approximately 22–33% across jaw series. Uncontrolled recurrence developed in ~21% of patients in one large series.[3][12]
• Distant metastasis is uncommon in conventional jaw chondrosarcoma but occurs more frequently with mesenchymal subtype (20% metastasis rate) and higher-grade tumors.[3][11]
• Overall actuarial survival at 5, 10, and 15 years for jaw/facial chondrosarcoma is approximately 81%, 65%, and 56%, respectively. Disease-specific 5-year survival for head and neck chondrosarcoma overall reaches ~87%.[3][10]
• Independent adverse prognostic factors include high histologic grade, recurrence, metastasis, and treatment with chemotherapy alone.[4]
• Mesenchymal chondrosarcoma carries a worse prognosis, with disease-specific mortality of ~24% and 5-year survival of ~53% in head and neck series.[10][11]

Surveillance

• Long-term follow-up is mandatory given the propensity for late recurrence. Recommended surveillance includes physical examination, imaging of the primary site, and chest imaging every 3–6 months for 5 years, then annually for a minimum of 10 years.[7]

Molecular Distinction by Anatomic Subsite

• The absence of IDH1/2 mutations in chondrosarcomas of the facial skeleton (maxilla, mandible) contrasts sharply with the high mutation rate (~86%) in skull base chondrosarcomas. This difference is hypothesized to reflect the intramembranous ossification origin of facial bones versus the endochondral origin of skull base bones. Clinicians should be aware that IDH mutation status in jaw chondrosarcoma does not parallel the pattern seen in appendicular or skull base tumors, and a negative IDH result does not exclude the diagnosis.[12][42]

Diagnostic Pitfall at the TMJ

• Low-grade chondrosarcoma of the mandibular condyle/TMJ region is frequently misdiagnosed as benign synovial chondromatosis or chondroma, sometimes leading to years of follow-up before malignancy is recognized. Any chondrogenic TMJ lesion with progressive growth, condylar destruction, or lateral pterygoid muscle infiltration should be regarded with high suspicion and biopsied.[19][25][26]